Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Innovation Pharmaceuticals Inc (IPIX) Message Board

New data analysis: chloroquine doesn't work very w

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 72446
(Total Views: 362)
Posted On: 03/24/2020 10:06:18 AM
Avatar
Posted By: Drano
New data analysis: chloroquine doesn't work very well if at all. The Chinese study involved only 30 patients, so to get actual conclusive results there needs to be a bigger clinical trial. It doesn't look good on the basis of this study.

Quote:
a key analyst has found trial data that contradict the conclusions from a small positive Chinese study that researchers initially based on their enthusiasm on.
....
The main goal of the study — virological clearance rate — was higher on the placebo arm at 93%, versus 87% on the hydroxychloroquine cohort. Temperature normalization was essentially the same — 1 day in both groups. Radiological progression on CT images favored hydroxychloroquine — 33% on the drug arm, compared to 47% in the control group — but these data are hard to interpret since there were just 5 versus 7 cases that progressed, Raffat cautioned.

“It really puzzles me why we’re seeing inaccurate characterizations of clinical data…having an honest discussion around emerging clinical data would actually help the progress,” he said.

“For instance, were the patients in this dosed early enough in this trial? (No disclosure on that). Also, were the baseline viral loads balanced across arms? Parsing through emerging data for these important drivers of success can help define what an effective treatment window and optimal candidate looks like.”


https://endpts.com/wall-street-analyst-finds-...-patients/

Looks to me like it's worth a try if someone is at risk of death -- but tragically it's not going to be the magic wonder drug we hoped for.




(0)
(0)




Innovation Pharmaceuticals Inc (IPIX) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us